Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 84
2002 91
2003 115
2004 170
2005 141
2006 118
2007 160
2008 170
2009 140
2010 158
2011 161
2012 203
2013 186
2014 197
2015 205
2016 163
2017 177
2018 170
2019 157
2020 211
2021 201
2022 161
2023 131
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

3,348 results

Results by year

Filters applied: . Clear all
Page 1
Biological therapies for myasthenia gravis.
Uzawa A, Utsugisawa K. Uzawa A, et al. Expert Opin Biol Ther. 2023 Mar;23(3):253-260. doi: 10.1080/14712598.2023.2184257. Epub 2023 Feb 28. Expert Opin Biol Ther. 2023. PMID: 36852951 Review.
Prostate cancer immunotherapy.
Mitsogiannis I, Tzelves L, Dellis A, Issa H, Papatsoris A, Moussa M. Mitsogiannis I, et al. Expert Opin Biol Ther. 2022 May;22(5):577-590. doi: 10.1080/14712598.2022.2027904. Epub 2022 Jan 16. Expert Opin Biol Ther. 2022. PMID: 35037527 Review.
Cell therapy for type 1 diabetes.
Loretelli C, Assi E, Seelam AJ, Ben Nasr M, Fiorina P. Loretelli C, et al. Expert Opin Biol Ther. 2020 Aug;20(8):887-897. doi: 10.1080/14712598.2020.1748596. Epub 2020 Apr 17. Expert Opin Biol Ther. 2020. PMID: 32299257 Free article. Review.
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L, Avancini A, Sposito M, Milella M, Rossi A, Pilotto S. Belluomini L, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3. Expert Opin Biol Ther. 2023. PMID: 36995069 Review.
Ravulizumab for the treatment of myasthenia gravis.
Vanoli F, Mantegazza R. Vanoli F, et al. Expert Opin Biol Ther. 2023 Mar;23(3):235-241. doi: 10.1080/14712598.2023.2185131. Epub 2023 Mar 8. Expert Opin Biol Ther. 2023. PMID: 36852670 Clinical Trial.
Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa A, Dimou V, Albelda SM. Klampatsa A, et al. Expert Opin Biol Ther. 2021 Apr;21(4):473-486. doi: 10.1080/14712598.2021.1843628. Epub 2020 Nov 12. Expert Opin Biol Ther. 2021. PMID: 33176519 Review.
Managing adverse events of sacituzumab govitecan.
Schlam I, Tarantino P, Tolaney SM. Schlam I, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1103-1111. doi: 10.1080/14712598.2023.2267975. Epub 2023 Dec 15. Expert Opin Biol Ther. 2023. PMID: 37800595 Review.
3,348 results